The First FOXG1 Patient has Received FRF-001
New York — September 7,2026 — The first FOXG1 patient has received FRF-001, the FOXG1 gene replacement therapy, in our first-in-human clinical trial.
In 2017, little was known about FOXG1 syndrome, and there was no path to treatment. Nine years later, the first child has received the first potential disease-modifying treatment for FOXG1 syndrome — developed by FOXG1 parents in the FOXG1 Research Center lab, in a trial independently sponsored by the FOXG1 Research Foundation.
In the words of our Chief Medical Officer, Dr. Brandon Henry:
"The dosing of the first participant in the FRF-001 clinical trial marks an important milestone for the FOXG1 community and years of work to bring this investigational gene therapy into the clinic. This milestone opens an important new chapter for the program and brings us one step further in the effort to develop a treatment for FOXG1 syndrome."
Information pertaining to the clinical trial will be available on ClinicalTrials.gov
About the FOXG1 Research Foundation
The FOXG1 Research Foundation is a global, parent-led nonprofit organization founded in 2017 with the mission to improve the lives of every person and family impacted by FOXG1 syndrome. FRF advances research, builds community, and is pioneering a new blueprint for rare disease drug development—accelerating the path to life-changing therapies for children worldwide. Learn more at FOXG1Research.org.
Media Contact press@foxg1research.org